IP Library Granted Patent US 9,464,106
Granted Patent B2
US 9,464,106 · App. 13/295,615 · Granted Oct 11, 2016

Oligonucleotides useful for detecting and analyzing nucleic acids of interest

Inventors: Sakari Kauppinen (Smørum, DK); Carsten Alsbo (Køge, DK); Peter S. Nielsen (Birkerød, DK); Daniel C. Jeffares (København N, DK); Tobias Mourier (København N, DK); Søren Mørk (Valby, DK); Peter Arctander (Askeby, DK); Niels Tommerup (Albertslund, DK); Niels Tolstrup (Klampenborg, DK); Henrik Vissing (Virum, DK); Søren Morgenthaler Echwald (Humlebaek, DK)
Assignee: Exiqon A/S
C07H19/06C07H19/16C07H21/00C07H23/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,464,106
App. No.
13/295,615
Granted
Oct 11, 2016
Kind
B2
Abstract

The invention features improved nucleic acids and methods for expression profiling of mRNAs, identifying and profiling of particular mRNA splice variants, and detecting mutations, deletions, or duplications of particular exons or other splice variants, e.g., alterations associated with a disease such as cancer, in a nucleic acid sample, e.g., a biological sample or a patient sample.

Claims (4)

1. A method of detecting a cDNA, said method comprising conducting PCR on said cDNA using an oligomer to hybridize to said cDNA, wherein said oligomer has a total of 8 or 9 nucleotides and at least 50% of said nucleotides are LNA nucleotide analogues, wherein said oligomer comprises at least one non-modified deoxyribonucleotide, and wherein said oligomer comprises a fluorophor and a quencher; and said method further comprising:

(i) when said oligomer is hybridized to said cDNA, detaching said fluorophor or said quencher from said oligomer using a polymerase having exonuclease activity during said PCR; and

(ii) detecting fluorescence from said fluorophor after its physical separation from said quencher, wherein said fluorescence is indicative of the presence of the cDNA.

2. The method of claim 1 , wherein at least 70% of said nucleotides are LNA nucleotide analogues.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 15, 2019
From: EXIQON A/S
To: QIAGEN GMBH
Reel/Frame 048341/0295 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 28, 2016
From: KAUPPINEN, SAKARI; ALSBO, CARSTEN; NIELSEN, PETER S.; JEFFARES, DANIEL C.; MOURIER, TOBIAS; MØRK, SØREN; ARCTANDER, PETER; TOMMERUP, NIELS; TOLSTRUP, NIELS; VISSING, HENRIK; ECHWALD, SØREN MORGENTHALER
To: EXIQON A/S
Reel/Frame 039282/0624 →
Priority Claims (1)
DK 2003 00752 · May 19, 2003 · national
Continuity (4)
Continuation 11643615 · Dec 21, 2006
Division 10690487 · Oct 21, 2003
Provisional Application 60420278 · Oct 21, 2002
Related Publication 20120157333A1 · Jun 21, 2012